ATON 004Alternative Names: ATON-004
Latest Information Update: 13 Aug 2015
At a glance
- Originator Aton Pharma
- Class Antidotes
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Poisoning
Most Recent Events
- 31 May 2010 Phase-II clinical trials in Poisoning in USA (unspecified route)